SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS Burmester, G. R., Garg, A., Van Hoogstraten, H., Graham, N., Boddy, A., Parrino, J., Genovese, M. C. WILEY-BLACKWELL. 2016: 40–41

View details for Web of Science ID 000375046500119